- Home
- BFS vs ARVN Comparison
BFS vs ARVN Comparison
Compare BFS & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BFS
- ARVN
- Stock Information
- Founded
- BFS 1993
- ARVN 2015
- Country
- BFS United States
- ARVN United States
- Employees
- BFS N/A
- ARVN N/A
- Industry
- BFS Real Estate Investment Trusts
- ARVN Biotechnology: Pharmaceutical Preparations
- Sector
- BFS Real Estate
- ARVN Health Care
- Exchange
- BFS Nasdaq
- ARVN Nasdaq
- Market Cap
- BFS 770.5M
- ARVN 680.6M
- IPO Year
- BFS 1993
- ARVN 2018
- Fundamental
- Price
- BFS $29.98
- ARVN $9.52
- Analyst Decision
- BFS
- ARVN Buy
- Analyst Count
- BFS 0
- ARVN 23
- Target Price
- BFS N/A
- ARVN $17.61
- AVG Volume (30 Days)
- BFS 76.3K
- ARVN 2.6M
- Earning Date
- BFS 11-06-2025
- ARVN 11-03-2025
- Dividend Yield
- BFS 7.87%
- ARVN N/A
- EPS Growth
- BFS N/A
- ARVN N/A
- EPS
- BFS 1.32
- ARVN N/A
- Revenue
- BFS $277,902,000.00
- ARVN $372,800,000.00
- Revenue This Year
- BFS $6.92
- ARVN $1.01
- Revenue Next Year
- BFS $4.90
- ARVN N/A
- P/E Ratio
- BFS $22.72
- ARVN N/A
- Revenue Growth
- BFS 5.23
- ARVN 299.57
- 52 Week Low
- BFS $29.83
- ARVN $5.90
- 52 Week High
- BFS $42.39
- ARVN $29.61
- Technical
- Relative Strength Index (RSI)
- BFS 29.42
- ARVN 59.47
- Support Level
- BFS $29.97
- ARVN $8.78
- Resistance Level
- BFS $30.75
- ARVN $10.29
- Average True Range (ATR)
- BFS 0.53
- ARVN 0.55
- MACD
- BFS -0.09
- ARVN -0.01
- Stochastic Oscillator
- BFS 3.08
- ARVN 52.25
About BFS Saul Centers Inc.
Saul Centers Inc is a self-managed real estate investment trust which invests in, operates and develops retail and commercial properties. The company's portfolio includes community and neighbourhood shopping centres, office properties, and mixed-use properties. Properties are located in the Washington, D.C. and Batlimore metropolitan areas. Saul Centers operates through two business segments: shopping centers, which contribute the maximum portion of total revenue; and mixed-use properties. Maximum tenants include grocery stores, discount department stores, and drug stores.
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.